Please ensure Javascript is enabled for purposes of website accessibility

DexCom Reports Q4 Earnings, Beats EPS and Revenue Targets

By Mark Prvulovic - Feb 13, 2020 at 7:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the medical device manufacturer gained ground on the news.

On Thursday afternoon, DexCom (DXCM 1.62%) announced its fourth-quarter and full-year financial results. The maker of continuous glucose monitoring systems for diabetes management reported an overall strong quarter during which key metrics beat Wall Street's expectations.

Revenue came in at $462.8 million, up 37% from the $338 million it brought in during Q4 2018. While sales growth in the U.S. market was strong, its biggest increase came from international markets, where sales rose by 52%. The domestic market still provides for 81% of the company's total income, however.

DexCom's GAAP net income was $92.7 million in Q4, a marked turnaround from the $179.7 million GAAP net loss it produced in the year-ago period.

A picture of a financial statements and a graph with a pen on top.

Image source: Getty Images.

One metric that changed noticeably for the worse was DexCom's cash position, which fell from $1.14 billion at the close of 2018 to just $446.2 million as of the end of 2019.

For the most part, however, the company has exceeded analysts' expectations. Wall Street had expected $441.0 million in quarterly revenue for the company, a figure that DexCom beat handily, while analysts' consensus EPS forecast of $0.74 turned out to be well below the GAAP EPS of $1.00 that the biotech company reported.

Further details

DexCom is a medical device manufacturer known for its diabetes monitoring systems, and its technology is a core feature in the products of a number of insulin pump makers, such as Tandem Diabetes Care. DexCom's stock rose 4.9% in after-hours trading Thursday following the quarterly release.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DexCom, Inc. Stock Quote
DexCom, Inc.
$321.23 (1.62%) $5.11
Tandem Diabetes Care Stock Quote
Tandem Diabetes Care
$71.99 (-1.37%) $-1.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.